Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2938
Source ID: NCT04772729
Associated Drug: Insulin Faster Aspart (Fiasp, Novo Nordisk)
Title: Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Diabetes type1|Diabetes Mellitus, Type 1
Interventions: DRUG: Insulin faster aspart (Fiasp, Novo Nordisk)
Outcome Measures: Primary: Glycaemia difference in time in range (TIR) 70-180mg/dl, at week 4 of the study|Glycaemia difference in time in range (TIR) 70-180mg/dl, at week 8 of the study | Secondary: Glycaemia difference in time below range (TBR), at weeks 4 and 8 of the study|Glycaemia difference in time above range (TAR), at weeks 4 and 8 of the study|Glycaemia difference in the coefficient of variation (CV), at weeks 4 and 8 of the study|Difference in the average glycemia levels + standard deviation, at weeks 4 and 8 of the study|Difference in Total Daily Dose (TDD) of insulin, at weeks 4 and 8 of the study|Difference in the basal rate of insulin, at weeks 4 and 8 of the study
Sponsor/Collaborators: Sponsor: Medical University of Warsaw
Gender: ALL
Age: CHILD
Phases: PHASE4
Enrollment: 77
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2021-03-01
Completion Date: 2024-03-01
Results First Posted:
Last Update Posted: 2021-02-26
Locations:
URL: https://clinicaltrials.gov/show/NCT04772729